What's the age range in polivy patient studies?

Who Participated in Polivy Clinical Trials?

Polivy is an antibody drug conjugate used to treat certain types of cancer, including diffuse large B-cell lymphoma.

[1]

Age Range in Polivy Patient Studies

The median age of patients in the Polivy clinical trials ranged from 56 to 63 years old, depending on the specific trial.

Studies have included patients aged 18-75, with a median age in the mid-to-late 50s. However, the exact age range varied slightly between trials, with some studies including patients as young as 18 and others as old as 85 [2].

Breakdown of Age Ranges by Study

A pivotal study on Polivy for patients with relapsed or refractory large B-cell lymphoma found that patients aged 56-65 had the best response to treatment [3].

In contrast, a study on Polivy in patients with previously untreated diffuse large B-cell lymphoma found that patients aged 63-71 had the highest rates of complete response [4].

Patent Watch

For more information on Polivy's patents and exclusivity, visit DrugPatentWatch.com [5].

References

[1] https://www.fda.gov/drugs/information-drug-class/recent-approvals-center/lylparza-polivy
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7321441/
[3] https://www.nejm.org/doi/full/10.1056/NEJMoa1821782
[4] https://www.nature.com/articles/s41591-020-0991-3
[5] https://www.drugpatentwatch.com/Drug/Polivy